{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0001525",
      "entity_text" : "angiogenesis",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04167",
      "entity_text" : "anti-VEGF monoclonal antibodies",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Receptor tyrosine kinase inhibitors and anti-VEGF monoclonal antibodies used to inhibit angiogenesis show limited benefit in tumors.",
  "reading_complete" : "2020-08-08T10:39:44Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T10:36:57Z",
  "trigger" : "inhibit",
  "evidence" : [ "anti-VEGF monoclonal antibodies used to inhibit angiogenesis" ],
  "pmc_id" : "6927555",
  "score" : 0
}